Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Androgenic Alopecia Therapeutics: Global Pipeline Analysis Report 2017 by Phase, Molecule Type, Route of Administration and Company -

Research and Markets
Posted on: 07 Mar 18

The "Androgenic Alopecia Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other" report has been added to's offering.

The study analyzed that the androgenic alopecia therapeutics pipeline comprises approximately 24 active drug candidates in different stages of development.

According to the research findings, various new technology platforms are being used by the companies for developing drug candidates to treat the disease. For instance, KINect technology platform, a kinase-focused drug discovery technology platform is used to manufacture, soft Janus kinase inhibitors, a Pre-Clinical drug candidate by Aclaris Therapeutics, Inc.

The positive clinical results of androgenic alopecia drug candidates have been driving the pipeline growth. Many drug candidates have shown positive clinical results and are proceeding further towards development. In February 2016, Cassiopea S.p.A. reported the top-line results from the proof of concept, Phase II clinical trial of Breezula (CB-03-01), in androgenic alopecia and it was found that Breezula, met both its two pre-defined co-primary efficacy endpoints, increase in total area hair count within 1 cm2 (TAHC) and subject hair growth assessment (HGA) at six months. Breezula also demonstrated favorable safety profile.

In August 2017, Aclaris Therapeutics, Inc. acquired Confluence Life Sciences, Inc., a privately held biotechnology company for a consideration of $10 million in cash and issued approximately 350,000 shares of its common stock, with a value of approximately $10 million on the closing date to expand the dermatological pipeline of Aclaris Therapeutics, Inc.

Some of the key players developing drugs for the treatment of androgenic alopecia therapeutics include GlaxoSmithKline plc, Almirall S.A., Allergan plc, RepliCel Life Sciences Inc. and others.

Report Segmentation

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

Key Topics Covered:

Chapter 1. Research Background

Chapter 2. Research Methodology

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

Chapter 5. Androgenic Alopecia Therapeutics Pipeline Analysis by Phase (2017)

Chapter 6. Clinical Trials Analysis

Chapter 7. Competitive Landscape Analysis

Chapter 8. Company Profiles

  • Merck & Co. Inc.
  • Allergan Plc
  • Almirall S.A.
  • RepliCel Life Sciences Inc.
  • RiverTown Therapeutics Inc.

For more information about this report visit

View source version on

Business Wire

Last updated on: 07/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.